TPIV100 + TPIV110

TPIV100 + TPIV110 is a combination of two investigational **multi-epitope peptide vaccines targeting the HER2/neu protein**, intended as immunotherapies for **HER2-positive breast cancer**. Both vaccines are designed to induce strong T-cell immune responses against cells expressing HER2/neu, an oncogenic driver in 15–20% of breast cancers. - **TPIV100** targets four HER2 antigens and demonstrated high rates of T-cell response in Phase 1 trials, with immune responses in >90% of patients. - **TPIV110** was developed as a next-generation vaccine, targeting five HER2 antigens selected for broader population coverage and more durable responses. Both vaccines aim to enhance anti-tumor immunity, support memory immune responses, and potentially reduce recurrence or progression in HER2-positive breast cancer. They are intended to be used alongside standard treatments, such as surgery, chemotherapy, and HER2-targeted antibodies (e.g., trastuzumab)[6][13][15].

Other names

TPIV 100/110HER2neu+ vaccine